A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Recruiting · NCT05636215 · Registry updated 2025-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-03-20 | NCT05636215 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | 82 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Cancer Hospital of Chongqing University | Chongqing | China | 1 |
| Monash Health | Clayton | Australia | 74 |
| Peking University Cancer Hospital | Beijing | China | 32 |
| Scientia Clinical Research Ltd | Randwick | Australia | 11 |
| Sunshine Coast University Private Hospital | Sunshine Coast | Australia | 1 |
| Westmead Hospital | Sydney | Australia | 32 |